←
Ed Reznik1,008 posts
Ed Reznik avatar✓

Ed Reznik ✓

@EdReznik

Developing computational approaches to studying metabolism in cancer, find our publications here: scholar.google.com/citations…

◷ Joined October 2013▧ 118 Photos and videos
Laura Kida avatar
⟳ Ed Reznik retweeted
Laura Kida@LauraCKida·Nov 16

About 90% of RNA molecules in our cells are tRNAs. To date, we have mostly been blind to their abundance and regulation in single-cell sequencing. Today, I’m excited to share a new manuscript from my MD/PhD work biorxiv.org/content/10.64898…

Ron S. Gejman MD, PhD avatar
⟳ Ed Reznik retweeted
Ron S. Gejman MD, PhD@rongejman·Nov 11

One of the major fascinations of my career thus far is understanding why the immune system fails to control or eliminate some immunogenic cancers. Cancer dormancy brings this question into sharp clinical focus: why do some cancers treated with curative intent come back years or decades after treatment? What role does the immune system play in keeping residual cancer cells from growing in the meantime, why aren’t residual cells eliminated, and what allows them to grow again? We put together a review on immune evasion in cancer dormancy and metastatic reactivation—now out in @trendscancer — with @GizemEfePhD @LuthriaKaran and with thanks to @BizarMd for the opportunity to write on this important topic. There’s been a lot of progress in understanding how the immune system controls metastatic outgrowth, how dormant cancer cells escape elimination, and how inflammation can allow them to reawaken. But most of what we know mechanistically comes from mouse models. Studying this in patients is difficult. The cells are rare, scattered across tissues, and clinically silent. Finding them is hard; figuring out what they’re doing and how they interact with surrounding immune cells is harder. We discuss what we’ve learned and approaches that could help us study these processes directly in patients. Understanding this biology is essential if we want to prevent late metastatic relapse. I think this deserves more attention and research investment. authors.elsevier.com/c/1o5RM…

Marcus Goncalves avatar
⟳ Ed Reznik retweeted
Marcus Goncalves@MarcusDGon·Nov 11

Adding new T-REx data to my plot of muscle loss vs weight loss from GLP1RAs. Still no convincing evidence that they cause disproportionate muscle loss.

Post attachment
Tony Hui avatar
⟳ Ed Reznik retweeted
Tony Hui@realTonyHui·Nov 3

Happy to report a rigorously controlled, comprehensively characterized mouse model in which cachexia is driven specifically by lung metastases, paired with a genetically identical, non-cachectic control group. Hope cachexia researchers find it useful. biorxiv.org/content/10.64898…

Gregory Ducker avatar
⟳ Ed Reznik retweeted
Gregory Ducker@gsducker·Oct 28

I'm very happy to share the final version of our paper, “MCT1-dependent mitochondrial lactate import sustains cardiac metabolism,” out in Nature! We show how lactate fuels heart mitochondria and helps protect the heart during stress. nature.com/articles/s41586-0… @UofUBiochem 1/10

Ben Zeskind avatar
⟳ Ed Reznik retweeted
Ben Zeskind@BenZeskind·Oct 17

Incredible study just published in @NatureMedicine by @EdReznik, @CentralParkWMD and colleagues at @MSKCancerCenter on one of the most important and least appreciated topics in oncology, the wasting of muscle and fat that drives weight loss in cancer patients, known as cachexia. Overall, they found a hazard ratio of ~3, meaning cancer patients with cachectic weight loss have TRIPLE the risk of death. Can counteracting cachexia help keep patients alive? This question is personal for me. In 2015 I lost a dear friend Alan Sonnenfeld to pancreatic cancer with cachexia. In 2018, my @Immuneering $IMRX colleagues and I presented data at AACR supporting the development of a MEK inhibitor with optimized pharmacokinetics to treat cachexia. We subsequently developed a third-generation MEK inhibitor, atebimetinib, designed to both reduce tumor volume and preserve body mass. This week atebimetinib was featured on the cover of Cancer Research, and a few weeks ago we presented data at the AACR Conference on Pancreatic Cancer showing how atebimetinib both reduced tumor volume and preserved body mass in pancreatic cancer patients treated in our Phase 2 study. Atebimetinib is now in Phase 3. @pfizer also deserves credit for developing ponsegromab for cancer cachexia, but beyond the two of us there is far too little effort in this area. In fact, companies rarely even report weight changes on their clinical trials. Hopefully @EdReznik's important publication will bring more attention to a topic that could make a big difference in keeping cancer patients alive! Dr. Reznik's Paper: nature.com/articles/s41591-0… Our 2018 Abstract: aacrjournals.org/cancerres/a… Our Cancer Research Paper: aacrjournals.org/cancerres/a… Our AACR Conference on Pancreatic Cancer Data: immuneering.com/wp-content/u… Key Ponsegromab Paper: nejm.org/doi/abs/10.1056/NEJ…

Ed Reznik avatar
Ed Reznik@EdReznik·Oct 12

My PhD advisor @dsegre once shared with me that every seven years you should change your scientific direction. I didn't anticipate that it would happen so naturally, but so it goes.

Ed Reznik avatar
Ed Reznik@EdReznik·Oct 12

Thank you as well to the patients and families who were cared for and treated at MSK. Our study is one small example of the huge and growing body of discoveries that are the inevitable consequence of data-driven cancer care.

Ed Reznik avatar
Ed Reznik@EdReznik·Oct 12

Thank you very much to our funders, especially the MSK Society and @psscra , who saw the opportunity to ask creative and incisive biological questions beginning with (but now moving well beyond) the most mundane of data, body weight.

Ed Reznik avatar
Ed Reznik@EdReznik·Oct 12

What do you do with this data? We now have predictive, calibrated models for risk of cachexia in several cancer types. As new therapies and interventions for cachexia are trialed, these can be used to power enrollment and identify those at highest need for early intervention